Hyperkalemia - ECG First, Stabilize, Shift, and Remove

Key Points

• Hyperkalemia severity is determined by concentration, rate of rise, kidney function, and ECG toxicity.
• IV calcium stabilizes myocardium but does not lower potassium.
• Insulin with glucose is a rapid intracellular-shift therapy.
• Nebulized beta-agonist is useful adjunctive therapy.
• Bicarbonate is most useful when significant metabolic acidosis is present.
• Shift therapies can wear off and cause rebound because potassium remains in the body.
• Dialysis provides definitive rapid removal in severe refractory hyperkalemia with impaired excretion.
• Monitor glucose after insulin because delayed hypoglycemia is common, particularly in kidney failure.

Algorithm

1. Verify the result when pseudohyperkalemia is plausible, but do not delay emergency treatment.
2. Obtain ECG and continuous monitoring in severe cases.
3. Give IV calcium for ECG toxicity or extreme clinical risk.
4. Give insulin plus glucose and adjunctive beta-agonist to shift potassium intracellularly.
5. Use bicarbonate when substantial acidemia contributes.
6. Initiate potassium removal with diuresis, binder, or dialysis based on kidney function and severity.
7. Recheck potassium and glucose and watch for rebound.
8. Identify and correct the underlying cause and medication contributors.

Clinical Synopsis & Reasoning

First confirm that the result is real without delaying treatment when the clinical picture is dangerous. Hemolysis, extreme thrombocytosis, leukocytosis, prolonged tourniquet time, or fist clenching can produce pseudohyperkalemia. A repeat nonhemolyzed specimen is appropriate for an unexpected asymptomatic elevation, but severe potassium with ECG abnormalities or compatible illness should be treated immediately. Common causes include acute or chronic kidney failure, RAAS inhibitors, mineralocorticoid antagonists, trimethoprim, potassium supplements, tissue breakdown, metabolic acidosis, insulin deficiency, and hypoaldosteronism.

Obtain an ECG promptly in severe hyperkalemia. Changes can progress from peaked T waves and PR prolongation to P-wave loss, QRS widening, sine-wave morphology, ventricular fibrillation, or asystole, but the relationship between potassium concentration and ECG pattern is imperfect. A normal ECG does not make marked hyperkalemia safe. Cardiac-membrane stabilization is the first pharmacologic priority when ECG toxicity is present or the clinical risk is extreme.

IV calcium does not lower serum potassium. Calcium chloride contains more elemental calcium and is often preferred through central access in peri-arrest situations; calcium gluconate is less irritating peripherally. Repeat calcium if ECG toxicity persists according to resuscitation protocol. After stabilization, insulin with glucose shifts potassium intracellularly within minutes. Nebulized albuterol provides an additional shift but should not be the sole therapy for severe hyperkalemia. Sodium bicarbonate is most useful when significant metabolic acidemia contributes and is not a reliable stand-alone potassium-lowering drug in every patient.

Treatment Strategy & Disposition

Potassium must ultimately leave the body. If the patient makes urine and volume status permits, loop diuretics can increase renal potassium excretion. Potassium binders may contribute to removal, but onset varies and they should not replace immediate membrane stabilization and intracellular shift in a patient with life-threatening ECG toxicity. Dialysis is the most reliable rapid removal strategy for severe hyperkalemia with kidney failure, refractory elevation, recurrent rebound, or inability to excrete potassium. Consult nephrology early when dialysis is likely.

After insulin, monitor glucose closely because hypoglycemia can occur hours later, especially in kidney failure. Recheck potassium after the initial shift therapies and continue monitoring for rebound because insulin and albuterol move potassium rather than remove it. Stop exogenous potassium and review RAAS inhibitors, mineralocorticoid antagonists, NSAIDs, trimethoprim, and other contributors. Do not permanently discontinue beneficial RAAS blockade without considering whether chronic potassium management, dose adjustment, diuretics, bicarbonate for metabolic acidosis, or newer binders can allow safe continuation.

Treat the cause: restore insulin in DKA, address rhabdomyolysis or tumor lysis, relieve obstruction, correct severe acidemia, and manage AKI. In a patient with cardiac arrest from suspected hyperkalemia, follow advanced resuscitation protocols while treating hyperkalemia aggressively.

Epidemiology / Risk Factors

• CKD and AKI are major risk factors.
• RAAS-inhibiting drugs increase risk, especially when several contributors coexist.
• Diabetes and hypoaldosteronism can produce chronic hyperkalemia.
• Tissue breakdown syndromes can cause rapid dangerous rises.

Investigations

Therapy Summary

Pharmacology

Prognosis / Complications

• Prompt treatment usually reverses electrophysiologic toxicity.
• Rebound is common if potassium is shifted but not removed.
• Recurrent hyperkalemia predicts future episodes unless medications and kidney disease are addressed.
• Severe untreated hyperkalemia can cause sudden cardiac arrest.

Patient Education / Counseling

• Avoid potassium-containing salt substitutes unless a clinician confirms they are safe.
• Review all medications and supplements after an episode.
• Know when repeat potassium testing is scheduled.
• Seek emergency help for weakness, palpitations, syncope, or a critically high laboratory result.
• Patients with CKD should discuss how to preserve beneficial kidney and heart medications while controlling potassium.

Notes

Emergency hyperkalemia therapy is a sequence, not a single drug. Calcium protects the heart, insulin and albuterol buy time, and removal prevents recurrence. Every severe episode should end with a plan for the cause, because potassium commonly rebounds after the temporary intracellular-shift therapies wear off.

References

1. KDIGO: Potassium Management Controversies Conference — Link
2. KDIGO: 2024 Clinical Practice Guideline for Evaluation and Management of CKD — Link